X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to focus on the type 1 diabetes and inflammatory bowel disease using Quell’s proprietary toolbox of Treg cell engineering modules, including its innovative Foxp3 Phenotype Lock, to develop autologous multi-modular Treg cell therapy candidates.
Lead Product(s): Treg-based Cell Therapy
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $2,085.0 million Upfront Cash: $85.0 million
Deal Type: Collaboration June 09, 2023
Details:
Proceeds to be used to fund clinical development of QEL-001 in liver transplantation, to accelerate development of its product pipeline across transplantation, neuroinflammatory and autoimmune diseases, and enhance its multi-modular engineered Treg platform.
Lead Product(s): QEL-001
Therapeutic Area: Immunology Product Name: QEL-001
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Jeito Capital
Deal Size: $156.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing November 29, 2021
Details:
The QEL-001 CAR is specific for HLA-A2, which localizes the activity of the CAR-Tregs to the site of the transplanted organ in HLA-A2 mismatch liver transplant patients (i.e. HLA-A2 negative recipients who received an HLA-A2 positive donor liver).
Lead Product(s): Multi-modular Engineered Treg Cell Therapy
Therapeutic Area: Immunology Product Name: QEL-001
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
